孟买医院主导的3期临床试验揭示了Favipiravir的疗效
在印度以轻度至中度COVID-19患者为目标
来自印度的最新消息
由孟买（Glenmark Pharmaceuticals）赞助，孟买突破医院（Breach Candy Hospital）领导的这项3期临床试验的结果令人鼓舞
发表在《国际传染病杂志》（IJID）上。
这是一本享誉全球的同行评议，已发表索引的开放获取期刊，每月发行一期，
由国际传染病学会在美国出版。
这些发现
也将出现在印刷版中。
研究的出版
在轻度至中度COVID-19中的标题为“口服依赖于RNA的RNA聚合酶抑制剂Favipiravir的功效和安全性：
随机
比较，
开放标签
多中心
Zarir F. Udwadia博士及其合著者撰写的“第3期临床试验”。
The Study
The Phase 3 study
was conducted in 150 patients as part of a randomized, open label, multicenter effort to investigate the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm),
in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19.
Glenmark Pharmaceutical reports that
the drug offered multiple treatment
benefits including faster time to clinical cure and it actually contributed to the delay in the need for supportive oxygen therapy.
Moreover, the investigators, led by Dr. Zarir F. Udwadia, MD, FRCP, FCCP, Breach Candy Hospital Mumbai,
that patients with COVID-19 with moderate symptoms were discharged from the hospital earlier than those patients that did not receive Favipiravir, with the median time to clinical cure reduced by 2.5 days compared with the control group.
Patients in the Glenmark clinical trial
received Favipiravir tablets 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, along with standard supportive care.
Randomization was stratified based on disease severity into mild and moderate.
The drug was well tolerated with no serious adverse events (SAEs) or deaths in the Favipiravir arm of the study.